Patient-derived pancreatic cancer-on-a-chip
2022
Rush University Medical Center, Chicago, USA
This study demonstrates a tumour-chip device engineered to mimic the pancreatic ductal adenocarcinoma (PDAC) tumour microenvironment by incorporating patient-derived organoids and stromal cells, specifically pancreatic stellate cells, and macrophages. Establishing patient-derived organoids in a multicellular microfluidic chip device prolongs cellular function and longevity and successfully establishes a complex organotypic tumour environment that incorporates desmoplastic stroma and immune cells. When primary cancer cells in monoculture were subjected to stroma-depleting agents, there was no effect on cancer cell viability. However, targeting stroma in the developed tumour-chip model resulted in a significant increase in the chemotherapy effect on cancer cells, thus validating the use of this tumour-chip device for drug testing.
Patient-derived pancreatic cancer-on-a-chip recapitulates the tumor microenvironment
Faraz Bishehsari
Added on: 04-28-2022
[1] https://www.nature.com/articles/s41378-022-00370-6
